Brief: Vivesto Gets MUMS Designation By FDA For Drug Paccal Vet

Vivesto AB

27/12/2023 07:10

Dec 27(Reuters) - Vivesto AB  VIVE.ST :
    * SAID ON FRIDAY DRUG CANDIDATE PACCAL VET GRANTED MUMS
(MINOR
USE/MINOR SPECIES) DESIGNATION BY THE U.S. FOOD AND DRUG
ADMINISTRATION (FDA) FOR TREATMENT OF SPLENIC HEMANGIOSARCOMA
(HSA) FOLLOWING SPLENECTOMY IN DOGS
    * PACCAL VET CAN GET 7 YEARS MARKET EXCLUSIVITY IN THE HSA
INDICATION FOLLOWING AN FDA APPROVAL OF THE PRODUCT

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN9859yd
 Further company coverage:  VIVE.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))